Mangalam Drugs & Organics has reported continued defaults on cash credit loans with Bank of Maharashtra and Bank of Baroda, exceeding 30 days. The defaults began in October 2025, signaling ongoing financial stress.
Mangalam Drugs & Organics Ltd Continues Loan Defaults
Mangalam Drugs & Organics Limited has filed a subsequent intimation regarding ongoing defaults on its cash credit loan facilities, with outstanding obligations reported as of June 15, 2026. The company continues to face challenges in meeting its debt obligations.
What just happened
The company reported that as of June 15, 2026, it has outstanding defaults on cash credit facilities with two banks: Bank of Maharashtra for ₹9.51 crore and Bank of Baroda for ₹6.06 crore. These defaults have been ongoing since October 2025.
Why this matters
These defaults indicate persistent liquidity issues and financial stress for Mangalam Drugs. Continued failure to service debt on cash credit facilities, essential for daily operations, raises concerns about the company's short-term financial health and operational stability.
The backstory
The defaults first occurred in October 2025 and have persisted beyond the 30-day threshold for both banks. This subsequent intimation highlights that the problem is chronic rather than a one-off event, suggesting deep-seated working capital management challenges.
What changes now
While the management has stated they are arranging to pay the overdue amounts, no specific timeline has been provided. Investors are advised to monitor future disclosures closely for any resolution or debt restructuring plans.
Risks to watch
The primary risk is the company's inability to resolve its liquidity constraints, which could lead to further operational disruptions or more severe financial repercussions.
Peer comparison
(No peer comparison data available in the filing)
Context metrics (time-bound)
- Defaults on cash credit facilities with Bank of Maharashtra (₹9.51 crore) and Bank of Baroda (₹6.06 crore) are ongoing since October 2025.
- Obligations outstanding as of June 15, 2026.
What to track next
Investors should closely watch for any updates on the repayment of these overdue amounts, potential debt restructuring, and the company's overall working capital management improvements.